相似文献
1
Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19.
Allergy. 2021 Mar;76(3):626-628. doi: 10.1111/all.14595.
2
Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19.
Arch Pharm (Weinheim). 2022 Mar;355(3):e2100367. doi: 10.1002/ardp.202100367. Epub 2021 Nov 21.
3
Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.
Med Hypotheses. 2020 Dec;145:110340. doi: 10.1016/j.mehy.2020.110340. Epub 2020 Oct 8.
4
Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?
Nutrition. 2021 Jan;81:110900. doi: 10.1016/j.nut.2020.110900. Epub 2020 Jun 20.
5
Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Inflammation. 2021 Oct;44(5):1865-1877. doi: 10.1007/s10753-021-01464-5. Epub 2021 Apr 16.
6
Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages.
FASEB J. 2021 Apr;35(4):e21441. doi: 10.1096/fj.202001952R.
7
Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications.
Molecules. 2022 Jul 28;27(15):4836. doi: 10.3390/molecules27154836.
8
Resolution of acute inflammation in the lung.
Annu Rev Physiol. 2014;76:467-92. doi: 10.1146/annurev-physiol-021113-170408. Epub 2013 Dec 2.
9
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
Clin Microbiol Infect. 2021 Oct;27(10):1520.e7-1520.e10. doi: 10.1016/j.cmi.2021.06.008. Epub 2021 Jun 15.
10
Specialized proresolving mediators in infection and lung injury.
Biofactors. 2021 Jan;47(1):6-18. doi: 10.1002/biof.1691. Epub 2020 Nov 28.
引用本文的文献
1
Aged garlic extract major constituent S-1-propenyl-l-cysteine inhibits proinflammatory mRNA expression in bronchial epithelial IB3-1 cells exposed to the BNT162b2 vaccine.
Exp Ther Med. 2025 Jun 10;30(2):153. doi: 10.3892/etm.2025.12903. eCollection 2025 Aug.
2
Distinct effects of glucocorticoid on pseudorabies virus infection in neuron-like and epithelial cells.
J Virol. 2025 Feb 25;99(2):e0147224. doi: 10.1128/jvi.01472-24. Epub 2025 Jan 24.
3
Natural 7,8-secolignans from fruit potently inhibit SARS-CoV-2 3CL and inflammation.
J Tradit Complement Med. 2024 Jan 16;14(5):501-509. doi: 10.1016/j.jtcme.2024.01.005. eCollection 2024 Sep.
4
Dexamethasone treatment influences tendon healing through altered resolution and a direct effect on tendon cells.
Sci Rep. 2024 Jul 3;14(1):15304. doi: 10.1038/s41598-024-66038-5.
5
Red Blood Cell-Hitchhiking Delivery of Simvastatin to Relieve Acute Respiratory Distress Syndrome.
Int J Nanomedicine. 2024 Jun 6;19:5317-5333. doi: 10.2147/IJN.S460890. eCollection 2024.
6
The severity of COVID-19 upon hospital admission is associated with plasma omega-3 fatty acids.
Sci Rep. 2024 May 3;14(1):10238. doi: 10.1038/s41598-024-60815-y.
7
Fmoc-FF hydrogels and nanogels for improved and selective delivery of dexamethasone in leukemic cells and diagnostic applications.
Sci Rep. 2024 Apr 30;14(1):9940. doi: 10.1038/s41598-024-60145-z.
8
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome.
Front Pharmacol. 2024 Feb 21;15:1351655. doi: 10.3389/fphar.2024.1351655. eCollection 2024.
9
Lipid mediators of inhalation exposure-induced pulmonary toxicity and inflammation.
Inhal Toxicol. 2024 Feb;36(2):57-74. doi: 10.1080/08958378.2024.2318389. Epub 2024 Feb 29.
10
Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection.
Life (Basel). 2024 Jan 31;14(2):210. doi: 10.3390/life14020210.
本文引用的文献
1
Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators.
J Immunol. 2021 Jan 15;206(2):329-334. doi: 10.4049/jimmunol.2001025. Epub 2020 Dec 4.
2
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19.
Allergy. 2020 Oct;75(10):2703-2704. doi: 10.1111/all.14420. Epub 2020 Jun 12.
4
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
5
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Resolution metabolomes activated by hypoxic environment.
Sci Adv. 2019 Oct 23;5(10):eaax4895. doi: 10.1126/sciadv.aax4895. eCollection 2019 Oct.
8
Resolvin D4 attenuates the severity of pathological thrombosis in mice.
Blood. 2019 Oct 24;134(17):1458-1468. doi: 10.1182/blood.2018886317.
9
Dexamethasone induces ω3-derived immunoresolvents driving resolution of allergic airway inflammation.
J Allergy Clin Immunol. 2018 Aug;142(2):691-695.e4. doi: 10.1016/j.jaci.2018.04.004. Epub 2018 Apr 24.
10
Glucocorticoid receptor control of transcription: precision and plasticity via allostery.
Nat Rev Mol Cell Biol. 2017 Mar;18(3):159-174. doi: 10.1038/nrm.2016.152. Epub 2017 Jan 5.
Zotero 插件